VanEck Associates’s Myriad Genetics MYGN Stock Holding History

VanEck Associates’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-111,205	Closed	-$3.78M	–	822
2015 Q2	$3.78M	Sell	111,205 -32,402	-23%	-$1.1M	0.02%	293
2015 Q1	$5.08M	Buy	143,607 +14,018	+11%	+$502K	0.03%	269
2014 Q4	$4.41M	Buy	129,589 +5,280	+4%	+$187K	0.03%	274
2014 Q3	$4.79M	Sell	124,309 -5,716	-4%	-$213K	0.03%	249
2014 Q2	$5.06M	Sell	130,025 -37,857	-23%	-$1.41M	0.02%	248
2014 Q1	$5.74M	Sell	167,882 -33,119	-16%	-$1.03M	0.03%	227
2013 Q4	$4.22M	Buy	201,001 +10,247	+5%	+$259K	0.02%	244
2013 Q3	$4.48M	Buy	190,754 +3,235	+2%	+$91.9K	0.02%	238
2013 Q2	$5.04M	Buy	+187,519	New	+$5.44M	0.03%	218

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VanEck Associates's MYGN Position: Q3 2015 in Review

VanEck Associates sold out of Myriad Genetics (MYGN) in Q3 2015, closing a stake of 111,205 shares — an estimated $3.78M sold.

VanEck Associates first reported a position in MYGN in Q2 2013 and held it in 9 quarters. The position peaked at $5.74M in Q1 2014. 234 funds tracked by Wall St. Rank hold MYGN as of Q3 2015.

VanEck Associates reported no remaining Myriad Genetics position as of Q3 2015 after selling out during the quarter.
VanEck Associates sold 111,205 Myriad Genetics shares in Q3 2015, an estimated $3.78M.
VanEck Associates first reported a position in Myriad Genetics in Q2 2013 and held it in 9 quarters.
VanEck Associates's Myriad Genetics position peaked at $5.74M in Q1 2014.
234 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2015.

Based on VanEck Associates's 13F filing for Q3 2015, filed 12 Nov 2015.